Iron chelator, prostate cancer conundrum on deck for ODAC
This article was originally published in Scrip
The summer is over, and with a newly reorganized and renamed office under his reign, Dr Richard Pazdur, director of the US FDA's OHOP – the Office of Hematology and Oncology Products, and not, as some might assume, a moniker for the "Orderly House of Pazdur" – is ready to get back to work, seeking to cram as much into the agency's 14 September advisory committee hearing as possible, which the cancer drug chief has tended to do at recent meetings.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.